Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

Figure 2

Effects of etifoxine on IRS-1 and Akt phosphorylation. (a and b) Huh7.5-SEAP cells (7 × 10⁵) were infected with 0.01 MOI of HCV and treated with etifoxine (0.01-1 μM) in a 6-well plate for 6 days after treatment. Cell lysates were collected and the phospho-IRS-1 (Tyr896), IRS-1, phospho-Akt (Ser473), Akt, and β-actin levels were detected by Western blot. Data are expressed as mean ±SD obtained from three individual experiments. < 0.05 vs. the medium control group; ^#p < 0.05 vs. the HCV-infected Huh 7.5-SEAP group.

(a)

(b)